argenx SE American Depositary Receipt (ARGX)
argenx SE (ARGX) Q3 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Beth DelGiacco – Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren – Chief Executive Officer Karl Gubitz – Chief Financial Officer Karen Massey – Chief Operating Officer Conference Call Participants Derek Archila – Wells Fargo Tazeen Ahmad – Bank of America James Gordon – JPMorgan Allison Bratzel – Piper Sandler Myles Minter – William Blair Alex Thompson – Stifel Danielle Brill – Raymond James Amy Li – Jefferies Yaron Werber – TD Cowen Vikram Purohit – Morgan Stanley Charles Pitman-King – Barclays Samantha Semenkow – Citi Gavin Clark-Gartner – Evercore ISI Suzanne van Voorthuizen – Kempen Joel Beatty – Baird Joon Lee – Truist Securities Victor Floc'h – BNP Paribas Xian Deng – UBS Leland Gershell – Oppenheimer Andy Chen – Wolfe Research Rajan Sharma – Goldman Sachs Thomas Smith – Leerink Partners Douglas Tsao – H. C. Wainwright David Seynnaeve – Petercam Emmanuel Papadakis – Deutsche Bank Simon Baker – Redburn Atlantic Operator Good morning.
3 Best Earnings Acceleration Stocks to Buy in a Strong Q4
With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
argenx: Myositis Data Could Add Billions In Value
argenx remains a dominant player in the anti-FcRn market, with Vyvgart approved for gMG, CIDP, and ITP in Japan. The ALKIVIA trial aims to expand Vyvgart's use in myositis, a rare autoimmune disease affecting at least 45,000 people in the U.S. Efgartigimod's FcRn inhibition reduces pathogenic IgG autoantibodies, showing potential across multiple autoimmune diseases.
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for July 31st
ARGX, VZLA, and SBFG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2024.
Argenx (ARGX) Upgraded to Buy: Here's What You Should Know
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
Here is how argenex SE (ARGX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
Friday, the FDA approved Argenx SE's ARGX Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
